Condition: Herpes Zoster · Sponsor: GlaxoSmithKline
The purpose of this study is to evaluate the reactogenicity, safety and immunogenicity of 2 doses of PED-HZ/su, GSK's vaccine candidate for the prevention of Herpes Zoster (HZ) in immunocompromised paediatric renal transplant recipients aged 1-17 years
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Brussels, Belgium | Recruiting |
| GSK Investigational Site | Ghent, Belgium | Recruiting |
| GSK Investigational Site | Leuven, Belgium | Recruiting |
| GSK Investigational Site | Liège, Belgium | Recruiting |
| GSK Investigational Site | Bordeaux, France | Recruiting |
| GSK Investigational Site | Lille, France | Recruiting |
| GSK Investigational Site | Marseille, France | Recruiting |
| GSK Investigational Site | Montpellier, France | Recruiting |
| GSK Investigational Site | Nantes, France | Withdrawn |
| GSK Investigational Site | Paris, France | Recruiting |
| GSK Investigational Site | Paris, France | Recruiting |
| GSK Investigational Site | Toulouse, France | Recruiting |
+ 19 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04006808